Skip to main content
Toggle navigation
Login
Search
Home
Program Book
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Email
Tweet
Jeffrey Liticker, PharmD BCOP
Medical Science Liaison
AstraZeneca
Poster(s):
(311) Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR+/HER2– advanced breast cancer: Characterization and management of frequent adverse events from the Phase 3 CAPItello-291 trial
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET
Email Jeffrey